In her publication from the BIG 02-98 study, LOI S demonstrated that increased lymphocytic infiltration correlates with better prognosis and enhanced efficacy of anthracycline-only chemotherapy in node-positive, ER-negative/HER2-negative BC (20). This evidence concerns the gene ERBB2 and breast cancer.